Drug Trial Radar · NCT07929844
Safety and Efficacy Study of SKX-16 in Participants With Mild to Moderate Distal Subungual Onychomycosis
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
204
Planned (sponsor's estimate)
Start
Nov 24, 2026
Primary completion
Sep 23, 2028
Study completion Oct 21, 2028
Sponsor
- Lead sponsor
- SATO Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 10, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a parallel group, double blind, vehicle-controlled study in which SKX-16 or vehicle (2:1 randomization) is applied once a day for 52 weeks to all affected toenails to participants with mild to moderate distal subungual onychomycosis (DSO) of the toenails involving between 20 to 50% of at least one great toenail at Screening.
Conditions
- Onychomycosis of Toenails
Interventions
SKX-16 (Luliconazole 10% Solution)Drug
Applied topically once daily for 52 weeks to all affected toenails identified by the investigator, followed by a Week 56 follow-up visit.
Vehicle solutionDrug
Applied topically once daily for 52 weeks to all affected toenails identified by the investigator, followed by a Week 56 follow-up visit, under the same conditions as the active arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Complete Cure at Week 56Time frame: 56 weeks
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
SKX16B01 Clinical Study - Site 105
Los Angeles, California
SKX16B01 Clinical Study - Site 101
San Francisco, California
SKX16B01 Clinical Study - Site 104
Miami, Florida
SKX16B01 Clinical Study - Site 109
Miami, Florida
SKX16B01 Clinical Study - Site 111
College Station, Texas
SKX16B01 Clinical Study - Site 119
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.